Pharma Update
Roche
PHESGO®
Phesgo: Rapid conversion in early launch countries
Significantly reducing healthcare costs and resource use
Treatment option
Phesgo reduces administration time & costs
Administration and observation schedule*
Strong global launch
Global Phesgo conversion rate at 35%*
Π
0.5 1.5 hours
HIV
PIV
5 - 8 min
15-30 min
Phesgo
•
·
.
2-6h
1h
<-1h-
Administration time
Ranges driven by differences in loading and maintenance
dose
Total time
40%
~2.5-7.5
hours
30%
20%
10%
~20-38 min
0%
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
20 21 21 21 21 22 22 22 22 23 23
85% of patients preferred Phesgo for subcutaneous administration over the intravenous formulation of Perjeta and Herceptin
Phesgo conversion rate at 35% in early launch countries; conversion in key markets: UK 92%, France, 59%, US: 19%, Germany 16%
Phesgo expanding eBC market share
•
Pivotal Phesgo on-body-injector (OBI) development ongoing
Source: O'Shaughnessy J, et al. ESMO 2020 (Abstract 165MO); H-Herceptin; P=Perjeta; IV-Intravenous; *Ranges driven by differences in loading and maintenance dose; *Perjeta/Phesgo conversion rate is based on volumes (vials)
and includes all launch countries after the 2nd quarter after the launch (38 countries); Phesgo in collaboration with Halozyme
56
56View entire presentation